The COVID-19 Vaccines: A Description of Adverse Events of Reactions Reported in Kansas.
COVID-19 vaccines
Kansas
adverse drug events
vaccination
vaccination refusal
Journal
Kansas journal of medicine
ISSN: 1948-2035
Titre abrégé: Kans J Med
Pays: United States
ID NLM: 101581958
Informations de publication
Date de publication:
2022
2022
Historique:
received:
02
09
2021
accepted:
18
10
2021
entrez:
4
4
2022
pubmed:
5
4
2022
medline:
5
4
2022
Statut:
epublish
Résumé
Coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and has spread rapidly throughout the world since its discovery in 2019. Three vaccines (Pfizer-BioNTech, Moderna/NIAID/BARDA, and Johnson & Johnson's Janssen) have been developed for use in the U.S. to aid in the fight against this virus, but have been scrutinized intensely for their efficacy and safety. It is important to understand and interpret the adverse events or reactions (AERs) associated with these vaccines in an objective and analytical manner. The goal of this descriptive study was to provide a resource outlining AERs associated with the three available vaccines in Kansas. Reports were obtained from the Vaccine Adverse Event Reporting System (VAERS), representing AERs observed in Kansas from December 11, 2020 to May 13, 2021. All data were screened and coded, and descriptive statistics were used to describe AERs based on vaccine manufacturer, patient age and biological sex, and reported deaths. Only 0.00068% of COVID-19 vaccine doses given in Kansas were associated with an AER (1,445/2,120,350). There were 4,297 individual AERs reported, and the most common were fatigue/tiredness (266; 6.2%), tingling/itching (251; 5.9%), fever (226; 5.3%), hives (223; 5.2%), and muscle/joint pain (209; 4.9%). Only 0.002% of COVID-19 vaccine doses in Kansas were associated with a death (38/2,120,350). The majority of VAERS reports were by females (1,139; 78.8%) and those aged 30 to 39 years (297; 20.6%). No reported AERs were unexpected compared to national data, and no VAERs report provided a causal relationship between vaccine administration and death. Vaccines are, and will continue to be, essential tools to fight COVID-19 in the quest to reach herd immunity. Providing a resource of potential AERs could aid in individual decisions to receive a vaccine and may help in the control of COVID-19. Future studies may include describing reported AERs for children under age 12 as the vaccines become available for those age groups, as well as reporting AERs for those who have received the vaccine after our study time period.
Identifiants
pubmed: 35371387
doi: 10.17161/kjm.vol15.15825
pii: 15-39
pmc: PMC8942589
doi:
Types de publication
Journal Article
Langues
eng
Pagination
39-47Informations de copyright
© 2022 The University of Kansas Medical Center.
Références
Vaccines (Basel). 2021 Jan 08;9(1):
pubmed: 33429880
Kans J Med. 2020 Oct 20;13:248-259
pubmed: 33173560
Brain. 2021 Mar 3;144(2):682-693
pubmed: 33313649
JAMA. 2020 Nov 24;324(20):2095-2096
pubmed: 33074293
N Engl J Med. 2021 Feb 4;384(5):470-471
pubmed: 33378607
EClinicalMedicine. 2021 Oct;40:101113
pubmed: 34490416
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
J Pharm Sci. 2021 Feb;110(2):615-618
pubmed: 33212162
J Intensive Care. 2016 Mar 23;4:18
pubmed: 27011789
Ecohealth. 2021 Mar;18(1):44-60
pubmed: 34086129
Viral Immunol. 2021 Apr;34(3):174-181
pubmed: 33351708
MMWR Morb Mortal Wkly Rep. 2020 Dec 18;69(50):1922-1924
pubmed: 33332292
JAMA Dermatol. 2021 Jun 1;157(6):716-720
pubmed: 33978670
Nat Med. 2021 Feb;27(2):225-228
pubmed: 33082575
JAMA. 2012 Feb 22;307(8):823-31
pubmed: 22357833
Medicine (Baltimore). 2021 May 7;100(18):e25837
pubmed: 33950996
JAMA. 2021 Apr 20;325(15):1575
pubmed: 33646285
MMWR Morb Mortal Wkly Rep. 2021 May 07;70(18):680-684
pubmed: 33956784
J Am Board Fam Med. 2021 Sep-Oct;34(5):898-906
pubmed: 34535515
Rev Med Liege. 2020 Sup;75(S1):170-175
pubmed: 33211442
Can Fam Physician. 2021 May;67(5):339-341
pubmed: 33980625